Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection.
John W. Babich(RaNA Therapeutics (United States)), Alan J. Fischman(Shriners Hospitals for Children), Michael J. Abrams(Rapt Therapeutics (United States)), Howard F. Solomon, Daniel J. Kroon, Marilyn C. Pike(Bethesda Hospital), Ronald G. Tompkins(Nashville Oncology Associates), Robert H. Rubin(Massachusetts General Hospital), Wendy Graham
PubMed
November 1, 1993
Cited by 95
Related Papers
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
|New England Journal of Medicine|2008|1.6k